Highlights of the EASL clinical practice guidelines on sclerosing cholangitis versus the latest Chinese guideline
10.3969/j.issn.1001-5256.2023.01.007
- VernacularTitle:欧洲与我国最新原发性硬化性胆管炎临床实践指南的比较
- Author:
Xin SUN
1
;
Tingyu ZHANG
1
;
Yuhao YAO
1
;
Ziwei GUO
1
;
Jiaxin ZHANG
1
,
2
;
Yongan YE
1
,
2
;
Xiaoke LI
1
,
2
Author Information
1. Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China
2. Institute of Liver Diseases, Beijing University of Chinese Medicine, Beijing 100700, China
- Publication Type:Guideline Interpretation
- Keywords:
Primary Sclerosing Cholangitis;
Diagnosis;
Therapeutics;
Surveillance;
Practice Guidelines as Topic
- From:
Journal of Clinical Hepatology
2023;39(1):43-49
- CountryChina
- Language:Chinese
-
Abstract:
In 2022, the European Association for the Study of the Liver issued Clinical practice guidelines on sclerosing cholangitis. With reference to the 2017 edition of Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline (2017) and in comparison to the corresponding contents in Guidelines on the diagnosis and management of primary sclerosing cholangitis (2021) issued by Chinese Society of Hepatology, Chinese Medical Association, in 2021, this article summarizes the updates in diagnosis, treatment, monitoring, and management of special populations and analyzes the basis for updated recommendations and their guiding significance in optimizing the clinical management of primary sclerosing cholangitis (PSC). The comparative analysis shows that the new version of the guidelines is similar to the Chinese guidelines in terms of diagnosis, treatment, and follow-up, and it is worth learning from the technical details such as the recommended dose of ursodeoxycholic acid and long-term follow-up plan. Since PSC is a chronic refractory disease, the drugs recommended by current guidelines cannot delay or reverse disease progression, and there is still a lack of consensus statements on immunotherapy and screening protocols for end-stage complications, which might be the directions for further research.
